Board of directors

Operative background from Pharmacia Biotech, Amersham and GE Healthcare. General manager for Separations Division 1999-2006. From 2006-2011 General manager for GE’s Life Sciences Business which was recently acquired by Danaher. From 2011 entrepreneur with different companies and board roles. Presently chairman in Grönsöö Säteri AB, Färjsundet Industri AB and Sophion A/S. Also Director in Biotage AB.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Kirsti has more than 30 years of experience from the Life Science and Pharmaceutical industries. She has previously held leading and executive positions at AstraZeneca, Pfizer and Swedish Orphan Biovitrim (Sobi), and was Managing Director for Pfizer Health AB during 2011-2014. Previous board assignments at PiiA, SwedenBio, OxThera AB and Pfizer Health AB. Current assignment as Board Director of Envirotainer Holding AB and Xbrane Biopharma AB. Kirsti holds a Master of Science and a Ph.D. in Pharmacy from the University of Oslo.

Johan Sedihn is a Master of Science in Industrial Economics from the Technical University of Linköping. He has more than 25 years of experience in the medical technology industry, most of his time in the Elekta Group. He has been involved in building operations during Elekta's growth in roles such as Executive VP Oncology and Chief Operating Officer. For 13 years, Johan was part of Elekta's Group Management and he was also CEO of subsidiaries in Sweden and the UK, and Chairman of the Board of dozens of subsidiaries around the world. Johan has experience from several board assignments. Presently chairman of the board at SyntheticMR AB (publ), Dirac Research AB (publ) and Sedvisor Limited.  Johan has been living in the UK since 2005.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.

Peter Nählstedt has more than 20 years of operative experience from leading positions in life science and industry. He provides consulting services and advisory in business development in the Life Sciences and technology area. During his time as CEO of Probi between 2014-2018 the company grew from 100 MSEK to 600 MSEK. Earlier experience include 4 years at Trelleborg Marine Systems and 8 years at GE Healthcare Life Science of which several years were spent in the US leading its Bioprocess business. Board Director at SenzaGen AB (publ), Chairman of the board at Double Good AB and Supersynbiotics AB.

Independence: Independent in relation to the company and the company management, independent in relation to major shareholders.